T Cell Activators Exhibit Distinct Downstream Effects on Chimeric Antigen Receptor T Cell Phenotype and Function
Open Access
- 1 June 2024
- journal article
- research article
- Published by Oxford University Press (OUP) in ImmunoHorizons
- Vol. 8 (6) , 404-414
Abstract
T cell activation is an essential step in chimeric Ag receptor (CAR) T (CAR T) cell manufacturing and is accomplished by the addition of activator reagents that trigger the TCR and provide costimulation. We explore several T cell activation reagents and examine their effects on key attributes of CAR T cell cultures, such as activation/exhaustion markers, cell expansion, gene expression, and transduction efficiency. Four distinct activators were examined, all using anti-CD3 and anti-CD28, but incorporating different mechanisms of delivery: Dynabeads (magnetic microspheres), TransAct (polymeric nanomatrix), Cloudz (alginate hydrogel), and Microbubbles (lipid membrane containing perfluorocarbon gas). Clinical-grade lentiviral vector was used to transduce cells with a bivalent CD19/CD22 CAR, and cell counts and flow cytometry were used to monitor the cells throughout the culture. We observed differences in CD4/CD8 ratio when stimulating with the Cloudz activator, where there was a significant skewing toward CD8 T cells. The naive T cell subset expressing CD62L+CCR7+CD45RA+ was the highest in all donors when stimulating with Dynabeads, whereas effector/effector memory cells were highest when using the Cloudz. Functional assays demonstrated differences in killing of target cells and proinflammatory cytokine secretion, with the highest killing from the Cloudz-stimulated cells among all donors. This study demonstrates that the means by which these stimulatory Abs are presented to T cells contribute to the activation, resulting in differing effects on CAR T cell function. These studies highlight important differences in the final product that should be considered when manufacturing CAR T cells for patients in the clinic.Keywords
This publication has 23 references indexed in Scilit:
- Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic MalignanciesBlood Cancer Discovery, 2022
- Expamers: a new technology to control T cell activationScientific Reports, 2020
- A Hydrogel-Integrated Culture Device to Interrogate T Cell Activation with Physicochemical CuesACS Applied Materials & Interfaces, 2020
- Novel DNA-based T-Cell Activator Promotes Rapid T-Cell Activation and ExpansionJournal of Immunotherapy, 2020
- Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22Molecular Therapy-Oncolytics, 2018
- A guide to manufacturing CAR T cell therapiesCurrent Opinion in Biotechnology, 2018
- Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cellsNature Biotechnology, 2018
- Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patientsCancer Immunology, Immunotherapy, 2013
- T Cell ActivationAnnual Review of Immunology, 2009
- Optimization of Human T-Cell Expansion Ex Vivo Using Magnetic Beads Conjugated with Anti-CD3 and Anti-CD28 AntibodiesJournal of Immunotherapy, 2004